Biogen Inc. (BIIB)
BIIB trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$228.90
-0.22% on the day
Market cap
$33.8B
Large cap
Revenue · 2025
$9.9B
+2.2% on 2024
Net income · 2025
$1.3B
13.1% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | BIIB on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0000875045 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $9.9B |
| Net income | $1.3B |
| Operating income | Not in SEC XBRL data |
| Net margin | 13.1% |
| Operating margin | Operating income not reported |
| Revenue growth | +2.2% |
| Cash | Not in SEC XBRL data |
| Total assets | $29.4B |
| P/E (computed) | 26.2× |
| P/S (computed) | 3.4× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B2 | 2025-05-08 |
| Latest annual report | 10-K | 2026-02-06 |
| Latest quarterly / interim | 10-Q | 2026-07-29 |
| Latest current report | 8-K | 2026-07-29 |
| Latest proxy | DEFA14A | 2026-04-28 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +4.8% |
| 1 month | +7.7% |
| 3 months | +11.4% |
| Year to date | +32.3% |
| 1 year | +60.9% |
| From 52-week high | 0.0% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| RVMD | Revolution Medicines Inc. | $188.44 | -2.84% | $40.4B |
| ARGX | argenx SE | $802.64 | -1.19% | $49.8B |
| BNTX | BioNTech SE American Depositary Share | $89.01 | -7.13% | $22.4B |
| EXEL | Exelixis Inc. | $59.51 | -0.52% | $14.7B |
| NBIX | Neurocrine Biosciences Inc. | $135.13 | -4.41% | $13.7B |
| MRNA | Moderna Inc. | $216.25 | +1.17% | $86.3B |
| HALO | Halozyme Therapeutics Inc. | $109.62 | -1.31% | $12.4B |
| TECH | Bio-Techne Corp | $72.48 | -0.11% | $11.4B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier